company background image
ZLD

Zelira Therapeutics ASX:ZLD Stock Report

Last Price

AU$1.88

Market Cap

AU$18.0m

7D

-12.6%

1Y

-75.6%

Updated

07 Aug, 2022

Data

Company Financials +
ZLD fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ZLD Stock Overview

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia.

Zelira Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zelira Therapeutics
Historical stock prices
Current Share PriceAU$1.88
52 Week HighAU$8.75
52 Week LowAU$0.90
Beta1.68
1 Month Change29.66%
3 Month Change44.62%
1 Year Change-75.58%
3 Year Change-86.23%
5 Year Change-86.23%
Change since IPO-53.29%

Recent News & Updates

Jul 14
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

ZLDAU PharmaceuticalsAU Market
7D-12.6%0.8%1.0%
1Y-75.6%-12.8%-7.9%

Return vs Industry: ZLD underperformed the Australian Pharmaceuticals industry which returned -12.8% over the past year.

Return vs Market: ZLD underperformed the Australian Market which returned -7.9% over the past year.

Price Volatility

Is ZLD's price volatile compared to industry and market?
ZLD volatility
ZLD Average Weekly Movement24.4%
Pharmaceuticals Industry Average Movement11.4%
Market Average Movement10.6%
10% most volatile stocks in AU Market17.5%
10% least volatile stocks in AU Market4.7%

Stable Share Price: ZLD is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 24% a week.

Volatility Over Time: ZLD's weekly volatility has increased from 16% to 24% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003n/aOludare Odumosuhttps://www.zeliratx.com

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia.

Zelira Therapeutics Fundamentals Summary

How do Zelira Therapeutics's earnings and revenue compare to its market cap?
ZLD fundamental statistics
Market CapAU$18.00m
Earnings (TTM)-AU$10.22m
Revenue (TTM)AU$1.30m

13.8x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ZLD income statement (TTM)
RevenueAU$1.30m
Cost of RevenueAU$862.50k
Gross ProfitAU$438.02k
Other ExpensesAU$10.66m
Earnings-AU$10.22m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.07
Gross Margin33.68%
Net Profit Margin-785.91%
Debt/Equity Ratio0%

How did ZLD perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ZLD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZLD?

Other financial metrics that can be useful for relative valuation.

ZLD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue8.9x
Enterprise Value/EBITDA-1.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ZLD's PS Ratio compare to its peers?

ZLD PS Ratio vs Peers
The above table shows the PS ratio for ZLD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average13x
EPN Epsilon Healthcare
1.7xn/aAU$9.4m
ACR Acrux
12.6xn/aAU$15.7m
ALA Arovella Therapeutics
27.6x78.0%AU$18.1m
NYR Nyrada
10.2xn/aAU$23.4m
ZLD Zelira Therapeutics
13.8x49.6%AU$18.0m

Price-To-Sales vs Peers: ZLD is expensive based on its Price-To-Sales Ratio (13.8x) compared to the peer average (13x).


Price to Earnings Ratio vs Industry

How does ZLD's PE Ratio compare vs other companies in the AU Pharmaceuticals Industry?

Price-To-Sales vs Industry: ZLD is expensive based on its Price-To-Sales Ratio (13.8x) compared to the Australian Pharmaceuticals industry average (9.1x)


Price to Sales Ratio vs Fair Ratio

What is ZLD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZLD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio13.8x
Fair PS Ratio17.6x

Price-To-Sales vs Fair Ratio: ZLD is good value based on its Price-To-Sales Ratio (13.8x) compared to the estimated Fair Price-To-Sales Ratio (17.6x).


Share Price vs Fair Value

What is the Fair Price of ZLD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ZLD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ZLD's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Zelira Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


49.6%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ZLD's forecast earnings growth is above the savings rate (1.8%).

Earnings vs Market: Insufficient data to determine if ZLD's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if ZLD's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ZLD's revenue (49.6% per year) is forecast to grow faster than the Australian market (5.7% per year).

High Growth Revenue: ZLD's revenue (49.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ZLD's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Zelira Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-25.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ZLD is currently unprofitable.

Growing Profit Margin: ZLD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ZLD is unprofitable, and losses have increased over the past 5 years at a rate of 25.9% per year.

Accelerating Growth: Unable to compare ZLD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZLD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.9%).


Return on Equity

High ROE: ZLD has a negative Return on Equity (-26.09%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Zelira Therapeutics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ZLD's short term assets (A$9.0M) exceed its short term liabilities (A$935.6K).

Long Term Liabilities: ZLD's short term assets (A$9.0M) exceed its long term liabilities (A$416.2K).


Debt to Equity History and Analysis

Debt Level: ZLD is debt free.

Reducing Debt: ZLD has no debt compared to 5 years ago when its debt to equity ratio was 6.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZLD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ZLD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 35.6% each year


Discover healthy companies

Dividend

What is Zelira Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ZLD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZLD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ZLD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZLD's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ZLD has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Oludare Odumosu

1.58yrs

Tenure

AU$559,617

Compensation

Dr. Oludare Odumosu serves as Director of Zelira Therapeutics Limited (formerly Zelda Therapeutics Ltd) since December 02, 2019. He serves as the Managing Director & Global Chief Executive Officer of Zelir...


CEO Compensation Analysis

Compensation vs Market: Oludare's total compensation ($USD385.78K) is above average for companies of similar size in the Australian market ($USD279.73K).

Compensation vs Earnings: Oludare's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ZLD's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: ZLD's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.8%.


Top Shareholders

Company Information

Zelira Therapeutics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Zelira Therapeutics Limited
  • Ticker: ZLD
  • Exchange: ASX
  • Founded: 2003
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$18.005m
  • Shares outstanding: 9.58m
  • Website: https://www.zeliratx.com

Location

  • Zelira Therapeutics Limited
  • 101 St Georges Terrace
  • Level 3
  • Perth
  • Western Australia
  • 6000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.